Bristol-Myers
Squibb Company (NYSE: BMY) today announced that its Board of
Directors has elected Dinesh C. Paliwal to the Board, effective July 1,
2013. Mr. Paliwal will serve as a member of the Committee on Directors
and Corporate Governance.
Paliwal, 55, who was born and raised in India, is currently the
chairman, president and chief executive officer of Harman International
Industries, Inc., a leading provider of premium audio and infotainment
systems for the automotive, consumer and professional markets, a
position he has held since 2008. He served as Harman’s president and
chief executive officer from 2007 to 2008. Prior to joining Harman, he
spent 22 years with ABB Group, a leader in power and automation
technologies with operations in approximately 100 countries, where he
last held the dual role of president, Global Markets and Technologies of
ABB Ltd. and chairman and chief executive officer of ABB North America.
While at ABB, Paliwal lived and worked in China for several years where
he also served for three years as economic advisor to the governor of
Guangdong Province. Paliwal serves on the board of ADT Corporation
(NYSE: ADT) and has previously served as the chairman of the U.S.
National Foreign Trade Council.
“We are very excited to have Dinesh join our Board,” said Lamberto
Andreotti, chief executive officer, Bristol-Myers Squibb. “He is an
accomplished leader who has worked in senior positions in Asia, Europe
and the United States. I am confident his insights gained from more than
30 years of broad international experience will be of great value to our
company.”
James
M. Cornelius, chairman of Bristol-Myers Squibb, added, “Dinesh is an
individual with high integrity. He has an impressive track record for
driving entrepreneurship and leading edge innovation as well as a sharp
focus on growth. We are fortunate to have him join our Board.”
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit www.bms.com
or follow us on Twitter at http://twitter.com/bmsnews.
Bristol-Myers SquibbMediaJennifer Mauer, 609-252-6579, jennifer.mauer@bms.comorInvestorsRanya Dajani, 609-252-5330, ranya.dajani@bms.comRyan Asay, 609-252-5020, ryan.asay@bms.com